ADXN Addex Therapeutics Ltd
0.0224CHF-2.61%Mkt Cap: 5.38M $P/E: —Today
Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for neurological disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enz…
Industry Peers
Biotechnology$127.24BUSDP/E 29.3
$76.05BUSDP/E 18.3
$74.84BUSD
$56.77BUSDP/E 37.1
$58.21BUSDP/E 35.5
$41.93BUSDP/E 17.9
$42.84BUSD
$41.27BUSDP/E 64.9
$32.61BUSDP/E 30.0
$29.97BUSDP/E 37.8
$25.66BUSD
$24.05BUSD
$23.24BUSDP/E 29.8
$22.98BUSD
$22.23BUSDP/E 30.6
$22.85BUSDP/E 14.4
$15.02BUSDP/E 15.9
$14.87BUSDP/E 17.3
$14.45BUSDP/E 18.4
$13.81BUSD
| Headline | Source | Time |
|---|---|---|
Older | ||
Addex Therapeutics Ltd (ADXN) (Q2 2026) Earnings Call Highlights: Regained GABAB PAM Rights and ... Addex Therapeutics Ltd (ADXN) posted a stable $3.4 million net loss, regained full GABAB PAM rights from Indivior, and raised $2.8 million to fund operations into Q4 2027. | ||
 Addex (ADXN) Q2 2026 Earnings Call Transcript Biotech regains GABAB rights, extends cash runway into Q4 2027. | ||